Eptifibatide Pregnancy and Breastfeeding Warnings
Brand names: Integrilin
Medically reviewed by Drugs.com. Last updated on Aug 16, 2023.
Eptifibatide Pregnancy Warnings
Eptifibatide has been assigned to pregnancy category B by the FDA. Animal data have failed to reveal evidence of fetotoxicity after administration of doses equivalent to 4 times the maximum recommended human daily dose. There are no adequate or controlled data from human pregnancy studies. Eptifibatide should only be used during pregnancy when need has been clearly established.
Eptifibatide Breastfeeding Warnings
There are no data on the excretion of eptifibatide in human milk. Because many drugs are excreted in human milk, caution should be exercised when eptifibatide is administered to a nursing mother.
See also
References for pregnancy information
- (2001) "Product Information. Integrilin (eptifibatide)." Schering Corporation
References for breastfeeding information
- (2001) "Product Information. Integrilin (eptifibatide)." Schering Corporation
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
